Pre-diagnosis excess acute care costs in alzheimer's patients among a US medicaid population

Applied Health Economics and Health Policy

Volumn 11, Issue 4, 2013, Pages 407-413

  Geldmacher, David S ^a   Kirson, Noam Y ^b   Birnbaum, Howard G ^b   Eapen, Sara ^b   Kantor, Evan ^b   Cummings, Alice Kate ^b   Joish, Vijay N ^c  

^a The University of Alabama at Birmingham   (United States)

^b ANALYSIS GROUP   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; EMERGENCY CARE; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT CARE; RETROSPECTIVE STUDY; UNITED STATES;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MIDDLE AGED; NEW JERSEY; UNITED STATES;

EID: 84880878762     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0038-9     Document Type: Article

References (28)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev., Washington: American Psychiatric Association; 2000.
2. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):257-62 (Epub 2011 Apr 21).
3. United States Preventive Services Task Force. The guide to clinical preventive services. Rockville: Agency for Healthcare Research and Quality; 2005.
4. Valcour VG, Masaki KH, Curb JD, et al. The detection of dementia in the primary care setting. Arch Intern Med. 2000;160(19):2964-8. (Pubitemid 32009054)
5. Boise L, Neal MB, Kaye J. Dementia assessment in primary care: results from a study in three managed care systems. J Gerontol A Biol Sci Med Sci. 2004;59(6):M621-6.
6. Magsi H, Malloy T. Underrecognition of cognitive impairment in assisted living facilities. J Am Geriatr Soc. 2005;53(2):295-8. (Pubitemid 41632557)
7. Sternberg SA, Wolfson C, Baumgarten M. Undetected dementia in community-dwelling older people: the Canadian Study of Health and Aging. J Am Geriatr Soc. 2000;48(11):1430-4.
8. Liu-Ambrose TY, Ashe MC, Graf P, et al. Increased risk of falling in older community-dwelling women with mild cognitive impairment. Phys Ther. 2008;88(12):1482-91. doi: 10.2522/ptj.20080117 (Epub 2008.Sep.26).
9. Kiecolt-Glaser JK, Glaser R, Shuttleworth EC, et al. Chronic stress and immunity in family caregivers of Alzheimer's disease victims. Psychosom Med. 1987;49(5):523-35. (Pubitemid 17156823)
10. Zarit S. The hidden victims of Alzheimer's disease: families under stress. New York: NYU Press; 1985.
11. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46(1):130-5. (Pubitemid 26156117)
12. Hill JW, Futterman R, Duttagupta S, et al. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002;58(1):62-70. (Pubitemid 34041939)
13. McCarten JR, Anderson P, Kuskowski MA, et al. Changes in outpatient costs following screening and diagnosis of cognitive impairment. Alzheimers Dement. 2010;6(4 Supplement):e19.
14. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology. 1996;47:166-77. (Pubitemid 26243879)
15. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51(7):937-44. (Pubitemid 36871141)
16. Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc. 2005;53(1):83-7. (Pubitemid 41647636)
17. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry. 2009;24(5):479-88.
18. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105-15. (Pubitemid 38844150)
19. Rascati KL, Smith MJ, Neilands T. Dealing with skewed data: an example using asthma-related costs of Medicaid clients. Clin Ther. 2001;23:481-98. (Pubitemid 32328753)
20. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993.
21. Taylor DH Jr, Sloan FA. How much do persons with Alzheimer's disease cost Medicare? J Am Geriatr Soc. 2000;48(6):639-46. (Pubitemid 30390453)
22. Harriet M, Lamb HM, Goa KL. Rivastigmine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics. 2001;19(3):303-18. (Pubitemid 32230944)
23. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990;147(8):1049-51. (Pubitemid 20257519)
24. Geldmacher DS, Kirson NY, Birnbaum HG, et al. Implications of early treatment among Medicaid patients with Alzheimer's disease. Alzheimers Dement. 2013. doi: 10.1016/j.jalz.2013.01.015
25. Iliffe S, Robinson L, Brayne C, et al. Primary care and dementia: 1. diagnosis, screening and disclosure. Int J Geriatr Psychiatry. 2009;24(9):895-901. doi: 10.1002/gps.2204.
26. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319-29.
27. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-83.
28. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424-35.